Synthesis of biotinylated photoaffinity probes based on arylsulfonamide γ-secretase inhibitors
- 15 August 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (16) , 4184-4189
- https://doi.org/10.1016/j.bmcl.2006.05.091
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Biomedical Innovation
- Takeda Pharmaceutical Company
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 36 references indexed in Scilit:
- γ-Secretase as a Therapeutic Target for Treatment of Alzheimers DiseaseCurrent Pharmaceutical Design, 2006
- Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897Biochemical Pharmacology, 2005
- Defining Molecular Targets to Prevent Alzheimer DiseaseArchives of Neurology, 2005
- Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase InhibitorThe Journal of Pharmacology and Experimental Therapeutics, 2005
- A novel series of potent γ-secretase inhibitors based on a benzobicyclo[4.2.1]nonane coreBioorganic & Medicinal Chemistry Letters, 2005
- Modulation of Notch Processing by γ-Secretase Inhibitors Causes Intestinal Goblet Cell Metaplasia and Induction of Genes Known to Specify Gut Secretory Lineage DifferentiationToxicological Sciences, 2004
- Aspartic Proteases Involved in Alzheimer's DiseaseChemBioChem, 2003
- Presenilin-dependent γ-secretase activity modulates thymocyte developmentProceedings of the National Academy of Sciences, 2001
- γ-Secretase inhibitors repress thymocyte developmentProceedings of the National Academy of Sciences, 2001
- Fenchylamine Sulfonamide Inhibitors of Amyloid β Peptide Production by the γ-Secretase Proteolytic Pathway: Potential Small-Molecule Therapeutic Agents for the Treatment of Alzheimer's DiseaseJournal of Medicinal Chemistry, 2000